349 related articles for article (PubMed ID: 10484947)
21. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety.
Davies A; Adena MA; Keks NA; Catts SV; Lambert T; Schweitzer I
Clin Ther; 1998; 20(1):58-71. PubMed ID: 9522104
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Blin O; Azorin JM; Bouhours P
J Clin Psychopharmacol; 1996 Feb; 16(1):38-44. PubMed ID: 8834417
[TBL] [Abstract][Full Text] [Related]
23. Extrapyramidal symptoms in patients treated with risperidone.
Simpson GM; Lindenmayer JP
J Clin Psychopharmacol; 1997 Jun; 17(3):194-201. PubMed ID: 9169965
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
25. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
Haas M; Unis AS; Armenteros J; Copenhaver MD; Quiroz JA; Kushner SF
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):611-21. PubMed ID: 20035579
[TBL] [Abstract][Full Text] [Related]
26. The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.
Seemüller F; Lewitzka U; Bauer M; Meyer S; Musil R; Schennach R; Riedel M; Doucette S; Möller HJ
Pharmacopsychiatry; 2012 Nov; 45(7):292-6. PubMed ID: 22614116
[TBL] [Abstract][Full Text] [Related]
27. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
28. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
[TBL] [Abstract][Full Text] [Related]
29. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
Devanand DP; Marder K; Michaels KS; Sackeim HA; Bell K; Sullivan MA; Cooper TB; Pelton GH; Mayeux R
Am J Psychiatry; 1998 Nov; 155(11):1512-20. PubMed ID: 9812111
[TBL] [Abstract][Full Text] [Related]
30. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
31. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Chouinard G
J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):36S-44S. PubMed ID: 7537286
[TBL] [Abstract][Full Text] [Related]
32. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Peuskens J
Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
[TBL] [Abstract][Full Text] [Related]
33. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety.
de Oliveira IR; Miranda-Scippa AM; de Sena EP; Pereira EL; Ribeiro MG; de Castro-e-Silva E; Bacaltchuk J
J Clin Pharm Ther; 1996 Oct; 21(5):349-58. PubMed ID: 9119918
[TBL] [Abstract][Full Text] [Related]
34. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.
Möller HJ; Bäuml J; Ferrero F; Fuger J; Geretsegger C; Kasper S; Kissling W; Schubert H
Eur Arch Psychiatry Clin Neurosci; 1997; 247(6):291-6. PubMed ID: 9477007
[TBL] [Abstract][Full Text] [Related]
35. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
36. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
Min SK; Rhee CS; Kim CE; Kang DY
Yonsei Med J; 1993 Jun; 34(2):179-90. PubMed ID: 7691017
[TBL] [Abstract][Full Text] [Related]
37. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
Riedel M; Eich FX; Möller HJ
Eur Psychiatry; 2009 Apr; 24(3):149-53. PubMed ID: 19070995
[TBL] [Abstract][Full Text] [Related]
38. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia.
Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Zhou W; Kapur S; Kane JM; Naber D
Schizophr Res; 2010 May; 118(1-3):176-82. PubMed ID: 20080036
[TBL] [Abstract][Full Text] [Related]
39. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
García-Cabeza I; Gómez JC; Sacristán JA; Edgell E; González de Chavez M
BMC Psychiatry; 2001; 1():7. PubMed ID: 11835695
[TBL] [Abstract][Full Text] [Related]
40. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
